Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Lexaria Bioscience (LEXX) over the last 15 years, with Q4 2025 value amounting to -$65.1 million.

  • Lexaria Bioscience's Retained Earnings fell 1989.06% to -$65.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$65.1 million, marking a year-over-year decrease of 1989.06%. This contributed to the annual value of -$63.5 million for FY2025, which is 2308.4% down from last year.
  • Per Lexaria Bioscience's latest filing, its Retained Earnings stood at -$65.1 million for Q4 2025, which was down 1989.06% from -$63.5 million recorded in Q3 2025.
  • Over the past 5 years, Lexaria Bioscience's Retained Earnings peaked at -$28.1 million during Q1 2021, and registered a low of -$65.1 million during Q4 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$45.8 million (2023), whereas its average is -$46.1 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first crashed by 920.57% in 2021, then crashed by 2546.45% in 2022.
  • Over the past 5 years, Lexaria Bioscience's Retained Earnings (Quarter) stood at -$33.8 million in 2021, then fell by 20.79% to -$40.9 million in 2022, then dropped by 14.9% to -$46.9 million in 2023, then dropped by 15.59% to -$54.3 million in 2024, then fell by 19.89% to -$65.1 million in 2025.
  • Its Retained Earnings stands at -$65.1 million for Q4 2025, versus -$63.5 million for Q3 2025 and -$60.8 million for Q2 2025.